The Interleukin-2 (IL-2) market is witnessing rapid growth due to advancements in cancer immunotherapy and autoimmune disease management. IL-2, a vital cytokine, promotes T-cell growth, with therapies ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The global brain cancer treatment market is rapidly evolving, driven by the increasing incidence of brain cancer and advancements in medical technology focusing on personalized medicine. With ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...

Hepatocellular carcinoma (HCC), the most common type of liver cancer and the third-leading cause of cancer-related deaths ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

Help is now there for those diagnosed with hard-to-treat blood cancers like leukemia and lymphoma, as new therapies are available to bolster the immune system by using novel engineered antibodies that ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

A new antibody treatment prevents cholesterol buildup in heart mitochondria and restores energy production, offering hope for ...